Project Details
Description
This project aims to explore if m6A modifications in circulating RNAs could be used as biomarker of clinical outcome after ACS. Furthermore, we aim to identify and functionally characterize ACS-specific m6A modifications in coding and non-coding RNAs. In order to achieve those aims, we have set the following specific research objectives:
1. To quantify total m6A modification in peripheral blood mononuclear cells (PBMCs) of ACS patients using the LC/MS method
2. To assess the biomarker potential of m6A modification
3. To identify ACS-specific m6A modifications in coding and non-coding RNAs using Nanopore sequencing
4. To perform an in vitro functional analysis of ACS-specific m6A modifications.
1. To quantify total m6A modification in peripheral blood mononuclear cells (PBMCs) of ACS patients using the LC/MS method
2. To assess the biomarker potential of m6A modification
3. To identify ACS-specific m6A modifications in coding and non-coding RNAs using Nanopore sequencing
4. To perform an in vitro functional analysis of ACS-specific m6A modifications.
| Acronym | MAACS |
|---|---|
| Status | Finished |
| Effective start/end date | 1/03/23 → 28/02/25 |
Funding
- European Commission: €191,760.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.